Does levodopa slow or hasten the rate of progression of Parkinson's disease?
- PMID: 16222436
- DOI: 10.1007/s00415-005-4008-5
Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Abstract
Levodopa therapy, as originally established by George Cotzias [2, 3], is the most powerful treatment for Parkinson's disease (PD). Levodopa's toxicity to neurons in vitro has raised concerns if it might hasten the progression of PD, although in vivo animal studies suggest it may be neuroprotective.
Objective: To discuss the results of the ELLDOPA trial that was carried out to determine if levodopa therapy influences the rate of progression of Parkinson's disease (PD).
Design: ELLDOPA was a multicenter, parallel-group, double-blind, dosage-ranging, randomized, controlled clinical trial.
Setting: Academic movement disorders clinics at 38 sites in the United States and Canada.
Patients: Three hundred and sixty-one patients with early PD of less than 2 years' duration who did not require symptomatic therapy.
Interventions: Subjects were randomly assigned to one of four treatment groups: carbidopa/levodopa 12.5/50 mg t. i. d. (N=92), 25/100 mg t. i. d. (N=88), 50/200 mg t. i. d. (N=91), or matching placebo (N=90). The dosage was gradually escalated over 9 weeks and then maintained until Week 40, at which time active treatment was withdrawn over 3 days. After 2 weeks without active treatment (Week 42), a final assessment of PD severity was obtained.
Outcome measures: The prespecified primary clinical outcome was the change in the total Unified Parkinson's Disease Rating Scale (UPDRS) between baseline and Week 42, comparing the four treatment groups. The primary neuroimaging component of the study in a subgroup of 142 subjects was the percent change in striatal (123)iodine 2-beta-carboxymethoxy-3-beta-(4-iodophe nyl)tropane (beta-CIT) uptake between baseline and Week 40 visits. The neuroimaging substudy utilized single photon emission computed tomography (SPECT) of the dopamine transporter.
Results: All dosages of levodopa exerted clinical benefit compared to placebo on the UPDRS scores throughout the study, including 2 weeks after discontinuing levodopa. The UPDRS scores at Week 42 failed to reach the level encountered in the placebo group (change of 7.8+/-9.0, 1.9+/-6.0, 1.9+/-6.9, and -1.4+/-7.8, for placebo, 150 mg/day, 300 mg/ day, and 600 mg/day, respectively, p<0.0001). Nausea (p=0.001) and dyskinesias (p=0.0001) were more common in the levodopa groups, especially with the higher dosages. Freezing appeared around the same time, but was more common in the placebo (14 %) and 150 mg/day group (10 %). The percent decline of beta-CIT uptake in the striatum was significantly more pronounced in the levodopa groups than the placebo group (-7.2%, -4%, -6%, and -1.4% in 600 mg/day, 300 mg/day, 150 mg/day, and placebo, respectively; p=0.035).
Conclusions: The clinical outcomes not only indicate that levodopa is effective in a dose-dependent manner in overcoming the signs and symptoms of PD, they also support the concept that the drug does not hasten the disease progression, but rather may slow down the rate of the disease. The clinical study failed to demonstrate any evidence of levodopa worsening early PD. However, the beta-CIT SPECT substudy indicates the opposite effect, namely that levodopa causes a more rapid decline in the integrity of the dopamine transporter located in the nigrostriatal nerve terminals in the striatum. These contradictory findings warrant further investigation into the effect of levodopa on PD. OTHER OBSERVATIONS: The ELLDOPA study was the first levodopa dose-response study ever conducted. It showed that dose is a factor in the cause of producing motor complications of dyskinesias and wearing-off, and that these can develop as early as 5 to 6 months. On the other hand, freezing of gait could be delayed or its occurrence reduced by high dosage levodopa, compared to placebo or low-dose levodopa. Withdrawal of levodopa over a 3-day step-down can be safely carried out without inducing the neuroleptic-like syndrome. The UPDRS was shown to be a reliable linear marker for disease progression. The ELLDOPA study also called into question the interpretation of beta-CIT SPECT in the presence of dopaminergic agents. Neuroimaging in ELLDOPA also showed that some people diagnosed with early PD do not have a dopaminergic deficit, calling into question how difficult the correct diagnosis may be in people with early symptoms of PD.
Similar articles
-
Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.Mov Disord. 2015 Jan;30(1):19-36. doi: 10.1002/mds.26120. Epub 2014 Dec 8. Mov Disord. 2015. PMID: 25488030 Review.
-
A new look at levodopa based on the ELLDOPA study.J Neural Transm Suppl. 2006;(70):419-26. doi: 10.1007/978-3-211-45295-0_63. J Neural Transm Suppl. 2006. PMID: 17017562 Review.
-
Levodopa and the progression of Parkinson's disease.N Engl J Med. 2004 Dec 9;351(24):2498-508. doi: 10.1056/NEJMoa033447. N Engl J Med. 2004. PMID: 15590952 Clinical Trial.
-
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.JAMA. 2002 Apr 3;287(13):1653-61. doi: 10.1001/jama.287.13.1653. JAMA. 2002. PMID: 11926889 Clinical Trial.
-
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.JAMA. 2000 Oct 18;284(15):1931-8. doi: 10.1001/jama.284.15.1931. JAMA. 2000. PMID: 11035889 Clinical Trial.
Cited by
-
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances.NPJ Parkinsons Dis. 2024 May 14;10(1):101. doi: 10.1038/s41531-024-00716-z. NPJ Parkinsons Dis. 2024. PMID: 38744872 Free PMC article.
-
Robustness of radiomic features in 123I-ioflupane-dopamine transporter single-photon emission computer tomography scan.PLoS One. 2024 Apr 11;19(4):e0301978. doi: 10.1371/journal.pone.0301978. eCollection 2024. PLoS One. 2024. PMID: 38603674 Free PMC article.
-
Real-world evidence on levodopa dose escalation in patients with Parkinson's disease treated with istradefylline.PLoS One. 2023 Dec 22;18(12):e0269969. doi: 10.1371/journal.pone.0269969. eCollection 2023. PLoS One. 2023. PMID: 38134023 Free PMC article.
-
Calcineurin inhibition protects against dopamine toxicity and attenuates behavioral decline in a Parkinson's disease model.Cell Biosci. 2023 Aug 1;13(1):140. doi: 10.1186/s13578-023-01068-6. Cell Biosci. 2023. PMID: 37528492 Free PMC article.
-
Effect of Medication and Deep Brain Stimulation on Gait in Parkinson's Disease and its Quantitative Analysis Using Mobishoe - A Comparative Study.Ann Indian Acad Neurol. 2023 Mar-Apr;26(2):156-160. doi: 10.4103/aian.aian_769_22. Epub 2023 Mar 17. Ann Indian Acad Neurol. 2023. PMID: 37179671 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical